426 related articles for article (PubMed ID: 19565485)
1. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.
Lau AC; Duong TT; Ito S; Yeung RS
Arthritis Rheum; 2009 Jul; 60(7):2131-41. PubMed ID: 19565485
[TBL] [Abstract][Full Text] [Related]
2. [Effects of intravenous immunoglobulin upon the overexpression and over-activation of nuclear factor-κB and matrix metalloproteinase-9 in murine model of Kawasaki disease].
Shangguan W; Du Z; Yang H; Zhang Y; Song M; Dong W
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):938-43. PubMed ID: 24854917
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
5. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
6. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
Stenbøg EV; Windelborg B; Hørlyck A; Herlin T
Scand J Rheumatol; 2006; 35(4):318-21. PubMed ID: 16882598
[TBL] [Abstract][Full Text] [Related]
7. Infliximab as a novel therapy for refractory Kawasaki disease.
Weiss JE; Eberhard BA; Chowdhury D; Gottlieb BS
J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313
[TBL] [Abstract][Full Text] [Related]
8. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[TBL] [Abstract][Full Text] [Related]
10. [Regulation of proinflammatory cytokine cascade in Kawasaki disease].
Furukawa S; Matsubara T; Ichiyama T
Nihon Rinsho; 2008 Feb; 66(2):258-64. PubMed ID: 18260323
[TBL] [Abstract][Full Text] [Related]
11. Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia.
Pul R; Kopadze T; Skripuletz T; Voss EV; Kieseier BC; Stangel M
J Neuroimmunol; 2009 Dec; 217(1-2):46-50. PubMed ID: 19833395
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
Inoue N; Takai S; Jin D; Okumura K; Okamura N; Kajiura M; Yoshikawa S; Kawamura N; Tamai H; Miyazaki M
Clin Chim Acta; 2010 Feb; 411(3-4):267-9. PubMed ID: 19945447
[TBL] [Abstract][Full Text] [Related]
13. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
14. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
[TBL] [Abstract][Full Text] [Related]
15. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease.
Wang CL; Wu YT; Lee CJ; Liu HC; Huang LT; Yang KD
J Pediatr; 2002 Oct; 141(4):560-5. PubMed ID: 12378198
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
17. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis.
Sugihara T; Sekine C; Nakae T; Kohyama K; Harigai M; Iwakura Y; Matsumoto Y; Miyasaka N; Kohsaka H
Arthritis Rheum; 2007 Apr; 56(4):1304-14. PubMed ID: 17394136
[TBL] [Abstract][Full Text] [Related]
18. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis].
Servel AC; Vincenti M; Darras JP; Lalande M; Rodière M; Filleron A
Arch Pediatr; 2012 Jul; 19(7):741-4. PubMed ID: 22652521
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease.
Lau AC; Duong TT; Ito S; Wilson GJ; Yeung RS
Clin Exp Immunol; 2009 Aug; 157(2):300-9. PubMed ID: 19604270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
